Chimeric antigen receptor (CAR) T cells represent a major advance for immunotherapy. However, while CAR T cell approaches against liquid tumors have been successful, results against solid tumors are less promising. In vitro assays such as flow cytometry and live-cell analysis are key to phenotyping and assessing immune cell function both prior to and following CAR introduction.
